Avior Wealth Management LLC Takes $400,000 Position in HealthEquity, Inc. $HQY

Key Points

• Avior Wealth Management LLC has purchased a new stake in HealthEquity, Inc., acquiring 3,821 shares valued at approximately $400,000.
• HealthEquity has seen several institutional investors increase their stakes, with 99.55% of the company's stock now owned by these entities.
• Wall Street analysts have raised their price targets for HealthEquity, with a consensus target price now at $119.77 and a majority rating the stock as a "Buy".

Avior Wealth Management LLC bought a new stake in HealthEquity, Inc. (NASDAQ:HQY - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,821 shares of the company's stock, valued at approximately $400,000.

Several other institutional investors and hedge funds also recently made changes to their positions in HQY. Wealth Enhancement Advisory Services LLC grew its position in shares of HealthEquity by 40.2% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,115 shares of the company's stock valued at $491,000 after purchasing an additional 1,466 shares during the last quarter. Versant Capital Management Inc bought a new stake in shares of HealthEquity in the first quarter valued at approximately $28,000. Rhumbline Advisers boosted its stake in shares of HealthEquity by 1.0% in the first quarter. Rhumbline Advisers now owns 269,977 shares of the company's stock valued at $23,858,000 after buying an additional 2,689 shares during the period. Whipplewood Advisors LLC boosted its stake in shares of HealthEquity by 5,060.0% in the first quarter. Whipplewood Advisors LLC now owns 774 shares of the company's stock valued at $68,000 after buying an additional 759 shares during the period. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in shares of HealthEquity by 40.0% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 3,137 shares of the company's stock valued at $277,000 after buying an additional 897 shares during the period. Institutional investors and hedge funds own 99.55% of the company's stock.

Insiders Place Their Bets

In other news, EVP Delano Ladd sold 6,000 shares of the stock in a transaction on Friday, September 19th. The stock was sold at an average price of $94.11, for a total value of $564,660.00. Following the completion of the transaction, the executive vice president directly owned 79,456 shares in the company, valued at approximately $7,477,604.16. This represents a 7.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Henry Fiore sold 1,794 shares of the stock in a transaction on Monday, July 7th. The shares were sold at an average price of $101.73, for a total value of $182,503.62. Following the completion of the transaction, the executive vice president owned 53,225 shares of the company's stock, valued at $5,414,579.25. The trade was a 3.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft boosted their price target on HealthEquity from $98.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, June 5th. Barrington Research reiterated an "outperform" rating and issued a $125.00 price target on shares of HealthEquity in a research note on Friday, August 29th. JMP Securities boosted their price target on HealthEquity from $110.00 to $117.00 and gave the company a "market outperform" rating in a research note on Wednesday, June 4th. Raymond James Financial reiterated a "strong-buy" rating and issued a $120.00 price target (up from $115.00) on shares of HealthEquity in a research note on Tuesday, July 8th. Finally, JPMorgan Chase & Co. upped their target price on HealthEquity from $125.00 to $126.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $119.77.

HealthEquity Stock Down 0.6%

NASDAQ HQY opened at $94.77 on Wednesday. The business has a fifty day moving average price of $92.52 and a two-hundred day moving average price of $93.91. The company has a debt-to-equity ratio of 0.47, a current ratio of 4.23 and a quick ratio of 4.23. HealthEquity, Inc. has a fifty-two week low of $74.07 and a fifty-two week high of $116.65. The stock has a market capitalization of $8.17 billion, a PE ratio of 57.44, a PEG ratio of 1.37 and a beta of 0.50.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.